To keep pace with the roaring success of its compounds, Genentech Inc. is buying Biogen Idec Inc.'s 60-acre biologics manufacturing plant in Oceanside, Calif. - the one that had been slated to make ill-fated Tysabri - for $408 million, thus boosting Genentech's drug-making capacity by about 30 percent. (BioWorld Today)